November 27th 2024
LBS-007, a novel targeted therapy, has received FDA fast track designation for the treatment of acute myeloid leukemia.
November 25th 2024
November 15th 2024
November 14th 2024
November 12th 2024
AGAVE-201 Data on Refractory cGvHD
May 7th 2024In this expert analysis of the AGAVE-201 trial data, the efficacy of a monoclonal antibody in treating graft versus host disease is discussed, with the lowest dose of 0.3 mg/kg administered every 2 weeks demonstrating the highest response rates, exceeding 75%.
Watch
Emerging Therapies for Chronic Graft-Versus-Host Disease
April 26th 2024This segment of the virtual tumor board presentation focuses on the clinical development and use of emerging therapies, specifically Belumosudil, for the management of chronic graft-versus-host disease (cGvHD) following hematopoietic stem cell transplantation.
Watch
RESPONSE Trial and Hydroxyurea Resistance
April 24th 2024Dr. Kuykendall comments on the high rates of hematocrit control and spleen response with ruxolitinib vs standard therapy in the RESPONSE trial for hydroxyurea-resistant/intolerant PV, and how these efficacy findings inform his treatment choices.
Watch
Factors in Selecting Initial PV Therapy
April 24th 2024Dr. Kuykendall explains the factors he considers when deciding on initial therapy for advanced PV patients, including comorbidities, individual patient factors like age and symptoms, and weighing the risks and benefits of different treatment options.
Watch
Factors Considered for Initial Therapy in Myelofibrosis
April 24th 2024Dr. Bose shares his perspective on the factors he considers when deciding on initial therapy for myelofibrosis, including his approach to timing of treatment initiation and how splenomegaly influences his choice of JAK inhibitors.
Watch
A Close Look at Hodgkin Lymphoma Treatment: Burke Reviews a Phase 2 Study
April 24th 2024John M. Burke, MD, discusses results from a phase 2 study which evaluated brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for the treatment of early-stage and advanced classical Hodgkin lymphoma.
Watch
Future Landscape of BPDCN Management
April 15th 2024Dr. Schiller will discuss the limitations of current treatment options for BPDCN in elderly transplant-ineligible patients and the emerging BPDCN research and data that they are most interested in to improve outcomes in this specific patient population.
Watch
Improving BPDCN Recognition and Diagnosis
April 15th 2024Dr. Schiller will discuss the red flag symptoms that increase suspicion of BPDCN, the process for diagnosis, and any challenges with differential diagnosis. Dr. Schiller will also provide strategies and resources to improve community recognition and diagnosis of this rare disease.
Watch
Current Therapies and Strategies for Transplant-Ineligible BPDCN Patients
April 15th 2024Dr. Schiller will discuss the limitations of currently available BPDCN treatments, the historical use of chemotherapy regimens and their potential to address unmet needs, and effective strategies for managing the financial burden and ensuring access to tagraxofusp for BPDCN patients.
Watch
Challenges and Unmet Needs in Transplant-Ineligible BPDCN Patients
April 15th 2024Dr. Schiller will discuss the key factors that make the transplant ineligible BPDCN patient population more difficult to treat, the major goals of therapy for these patients, and how the mechanism of action of tagraxofusp suggests potential efficacy in BPDCN.
Watch
Steroid-Refractory cGvHD: Emerging Treatment Options
April 12th 2024This segment explores the management of steroid-refractory cGvHD, highlighting the data from clinical trials on agents like ibrutinib and ruxolitinib. The discussion delves into the potential benefits, risks, and optimal patient selection for these novel therapies.
Watch